FDA
-
-
-
-
-
-
-
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
-
-
-
-
-
-
-
Nuvectis Pharma's (NVCT) NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
-
-
-
-
-
-
-
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
-
-
-
-
-
-
-
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
-
-
-
-
-
-
-
Nuvectis Pharma (NVCT) to Join the Russell 2000 and Russell 3000 Indexes
-
-
-
-
-
-
-
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
-
-
-
-
-
-
-
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

